SAB Biotherapeutics (NASDAQ:SABS) Rating Increased to Strong-Buy at UBS Group

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by UBS Group to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

A number of other analysts have also recently commented on SABS. Guggenheim initiated coverage on SAB Biotherapeutics in a research report on Friday, December 19th. They issued a “buy” rating and a $15.00 price target on the stock. Chardan Capital reissued a “buy” rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a report on Thursday, December 18th. Leerink Partnrs raised SAB Biotherapeutics to a “strong-buy” rating in a research note on Wednesday, September 17th. Wall Street Zen raised SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of SAB Biotherapeutics in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $10.00.

SAB Biotherapeutics Stock Down 2.8%

Shares of SAB Biotherapeutics stock opened at $3.86 on Wednesday. SAB Biotherapeutics has a 1 year low of $1.00 and a 1 year high of $6.60. The firm has a market cap of $183.77 million, a price-to-earnings ratio of -1.25 and a beta of 0.58. The company has a 50-day moving average of $3.69 and a 200 day moving average of $2.78. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.49 and a quick ratio of 10.50.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.38. As a group, sell-side analysts anticipate that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

Several large investors have recently bought and sold shares of SABS. Vivo Capital LLC purchased a new stake in shares of SAB Biotherapeutics during the 3rd quarter valued at about $22,954,000. RA Capital Management L.P. bought a new position in SAB Biotherapeutics during the third quarter valued at approximately $8,847,000. Woodline Partners LP purchased a new stake in SAB Biotherapeutics in the third quarter worth approximately $5,730,000. Virtu Financial LLC purchased a new stake in SAB Biotherapeutics in the third quarter worth approximately $40,000. Finally, ADAR1 Capital Management LLC bought a new stake in SAB Biotherapeutics in the 3rd quarter worth approximately $30,000. 7.82% of the stock is currently owned by institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.